| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/07/2005 | WO2005030748A1 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics |
| 04/07/2005 | WO2005030740A1 Thiazoline derivative and use of the same |
| 04/07/2005 | WO2005030733A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof |
| 04/07/2005 | WO2005030732A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 04/07/2005 | WO2005030731A1 Gamma-secretase inhibitors |
| 04/07/2005 | WO2005030724A1 Piperazinyl-quinoline derivatives useful for the treatment of cns disorders |
| 04/07/2005 | WO2005030722A1 N-substituted-n-(4-piperidinyl) amide derivative |
| 04/07/2005 | WO2005030721A1 Piperidine derivative |
| 04/07/2005 | WO2005030720A1 Piperidine derivative having nmda receptor antagonistic activity |
| 04/07/2005 | WO2005030716A1 Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 |
| 04/07/2005 | WO2005030715A1 Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors |
| 04/07/2005 | WO2005030703A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN |
| 04/07/2005 | WO2005030333A2 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 04/07/2005 | WO2005030332A2 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 04/07/2005 | WO2005030260A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 04/07/2005 | WO2005030256A1 INHIBITION OF NERVE CELL DEATH BY INHIBITING DEGRADATION OF SHC3, ATF6 OR CREBL1 BY HtrA2 AND METHOD OF AMELIORATING NEURODEGENERATIVE DISEASES |
| 04/07/2005 | WO2005030235A1 Method of processing ginseng for medicinal use and composition |
| 04/07/2005 | WO2005030219A1 Method of stabilizing diarylvinylene compound |
| 04/07/2005 | WO2005030210A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 04/07/2005 | WO2005030148A2 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 04/07/2005 | WO2005016898A3 Stable polymorph of bifeprunox mesilate |
| 04/07/2005 | WO2005012269A8 Novel azole compound |
| 04/07/2005 | WO2005012256A8 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 04/07/2005 | WO2005000845A3 Bicyclic derivatives as nk-1 and nk-2 antagonists |
| 04/07/2005 | WO2004108760A3 Improved secretion of neublastin |
| 04/07/2005 | WO2004099394A3 A method for efficient transfer of human blastocyst-derived stem cells (hbs cells) from a feeder-supported to a feeder-free culture system |
| 04/07/2005 | WO2004089369A3 Methods and means for treating protein conformational disorders |
| 04/07/2005 | WO2004073741A8 Remedy for spinal injury containing interleukin-6 antagonist |
| 04/07/2005 | WO2004020189A8 Embossable and writable multilaminate backing construction |
| 04/07/2005 | WO2003090689A3 Neurodegenerative disorder treatment using gdnf secreting neural cells |
| 04/07/2005 | WO2003015783A8 Method of treating alcoholism or alcohol abuse |
| 04/07/2005 | US20050076398 Lysine starve rodent model for identifying modulators for treartment and prevention of gastrointestinal disorders |
| 04/07/2005 | US20050075480 Urotensin-II agonists and antagonists |
| 04/07/2005 | US20050075396 Modulation of type 2 diabetes and drug delivery |
| 04/07/2005 | US20050075394 Phenethanolamine derivatives for treatment of respiratory diseases |
| 04/07/2005 | US20050075393 Cyclopropane carboxylic acid for treatment of nervous system disorders and for slowing metabolism |
| 04/07/2005 | US20050075391 Nitric oxide donor composition and method for treatment of anal disorders |
| 04/07/2005 | US20050075386 Drugs from indocasbazole derivatives |
| 04/07/2005 | US20050075378 Modulators of peroxisome proliferator activated receptors (ppar) |
| 04/07/2005 | US20050075373 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/07/2005 | US20050075351 4-(Azaindol-3-yl)-quinazoline, 4-(azaoxindol-3-yl)-quinazoline, or 4-(diazaindol-3-yl)-quinazoline derivatives as glycogen synthase kinase inhibitors; Alzheimer's, Parkinson's, Huntington's disease; Down syndrome, amyotrophic lateral sclerosis; neurodegenerative and brain disorders; cognition activators |
| 04/07/2005 | US20050075339 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/07/2005 | US20050075336 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075330 Dipeptidyl peptidase inhibitors |
| 04/07/2005 | US20050075329 S-tofisopam, a prodrug or a salt thereof, free of its R enantiomer, and a carrier; may also contain one or more other anticonvulsants |
| 04/07/2005 | US20050075305 Therapeutic compositions and methods of treating glycolipid storage related disorders |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050075271 Crystalline beta2 adrenergic receptor agonist |
| 04/07/2005 | US20050075269 Substituted benzofuran-2-carboxamides derivatives |
| 04/07/2005 | US20050074852 Serine/threonine kinase (PKN) peptides for use in identifying modulators for treatment and prevention of inflammation, cancer, arteriosclerosis and psoriasis |
| 04/07/2005 | US20050074841 DNAs encoding mammalian histamine receptor of the H4 subtype |
| 04/07/2005 | US20050074819 Using ligand gated channel protein to identify modulators for prevention and treatment of tactile allodynia induced after nerve injury |
| 04/07/2005 | US20050074770 Cloned mammalian histamine H4 receptor that couples to G-protein; for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 04/07/2005 | US20050074764 Using presence of point mutations in nicotinic acetylcholine receptor (nACHR) gene as diagnostic/prognosic tool in detction and treatment of indicator of cardiovascular, nervous system, vision and pain disorders |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074507 Polyherbal formulation for hepatic and splenic disorders |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074461 Transdermal botulinum toxin compositions |
| 04/07/2005 | US20050074457 Simplified, high throughput screening for identification of heat shock protein 90 ligands selective for high affinity form |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | DE10350338B3 Use of Pelargonium plant parts or extracts for treating chronic and/or post-viral fatigue syndrome and/or disease-associated behavioral changes, e.g. depression and tiredness |
| 04/07/2005 | CA2581996A1 Buccal, polar and non-polar spray containing alprazolam |
| 04/07/2005 | CA2580730A1 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 04/07/2005 | CA2540243A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540242A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540239A1 Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540208A1 Amino acids with affinity for the alpha2delta-protein |
| 04/07/2005 | CA2540197A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 04/07/2005 | CA2540104A1 Water soluble nanoparticles comprising inclusion complexes |
| 04/07/2005 | CA2540083A1 Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| 04/07/2005 | CA2539976A1 Therapeutic beta aminoacids |
| 04/07/2005 | CA2539961A1 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 04/07/2005 | CA2539947A1 Igf-1 instructs multipotent adult cns neural stem cells to an oligodendroglial lineage |
| 04/07/2005 | CA2539727A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 04/07/2005 | CA2539042A1 Gamma-secretase inhibitors |
| 04/07/2005 | CA2538705A1 Ligands |
| 04/07/2005 | CA2538694A1 Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 |
| 04/07/2005 | CA2538263A1 Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors |
| 04/07/2005 | CA2536791A1 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics |
| 04/07/2005 | CA2506282A1 Use of galanthamine and the derivatives thereof in the production of medicaments |
| 04/06/2005 | EP1520854A2 Aza-Spirocompounds for the treatment of pain |
| 04/06/2005 | EP1520043A2 METHODS FOR THE IDENTIFICATION OF IKKa FUNCTION AND OTHER GEN ES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES |
| 04/06/2005 | EP1519939A2 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 04/06/2005 | EP1519933A1 Quinuclidine amide derivatives |
| 04/06/2005 | EP1519922A1 Di-aryl-substituted ethane pyridone pde4 inhibitors |
| 04/06/2005 | EP1519915A2 Tricyclic steroid hormone nuclear receptor modulators |
| 04/06/2005 | EP1519908A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 04/06/2005 | EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 04/06/2005 | EP1519753A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 04/06/2005 | EP1519746A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 04/06/2005 | EP1519740A2 Rapid improvement of cognition in conditions related to a-beta |
| 04/06/2005 | EP1519738A1 Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases |
| 04/06/2005 | EP1519735A2 Assays and implements for determining and modulating hsp90 binding activity |
| 04/06/2005 | EP1519733A1 Compositions for cancer therapy comprising saponins or sapogenins |
| 04/06/2005 | EP1519732A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 04/06/2005 | EP1519730A1 Novel use of imidazotriazinones |
| 04/06/2005 | EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 04/06/2005 | EP1519720A2 Novel formate salt of o-desmethyl-venlafaxine |
| 04/06/2005 | EP1519716A1 Extended-release tablets comprising divalproex sodium |